<DOC>
	<DOC>NCT02092077</DOC>
	<brief_summary>The purpose of this study is to support selection of an appropriate safe and efficacious dose for study in further development.</brief_summary>
	<brief_title>A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Criteria for Inclusion: Prepubertal boys ≥ 3 years to ≤ 11 years and prepubertal girls ≥ 3 years to ≤ 10 years growth hormone (GH) insufficiency Diagnosis criteria consistent with growth hormone research society consensus guidelines Patients with a previously treated pituitary tumor must have no tumor progression for at least the past year Physician determined rate of change in height less than 2 standard deviations per age group. Written Informed Consent Parent or legal guardian who is capable and willing to administer the study drug. Other criteria apply, please contact the investigator for more information Criteria for Exclusion: Any clinically significant medical condition as determined by the investigator, that is likely to affect growth Contraindications to rhGH treatment; History of or currently active malignancy, including pituitary tumors; Bone age, greater than chronological age or greater than 9 for girls or greater than 10 for boys within 3 months of screening. Patients with known diagnosis of diabetes or prediabetes Growth altering medications Allergies to the study medication components; Participation in another investigational study within 30 days of screening Any medical condition as judged by the investigator to interfere with patient participation or the objectives of the study Other criteria apply, please contact the investigator for more information</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Growth Hormone-Deficient</keyword>
	<keyword>recombinant human growth hormone</keyword>
</DOC>